Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma -A randomized double blind study-

Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma -A randomized double blind study- - Cancer vaccination therapy in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001732

Enrollment

Registered

2009-02-23

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the patients who have received trans-arterial infusion chemotherapy against advanced HCCs. Cancer vaccination the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have received trans-arterial infusion chemotherapy. 2. more than 20, less than 80 years of age. 3. Performance status (ECOG) of the patients are 0-2. 4. Child-Pugh class A or B. 5. Has adequate organ function as difined by following criteria. 1 WBC count more than 2000/mm3, less than 15000/mm3. 2 Plt count more than 50000/mm3. 3 AST and ALT less than 150IU/L. 4 T-Bil less than 3.0mg/dl. 5 Creatinine less than 3.0mg/dl. 6 Patients who have HLA-A*2402. 7 All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients judged inappropriated by doctors.

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
immunologicalresponse and clinical efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026